PMID- 35158785
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220219
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 3
DP  - 2022 Jan 20
TI  - Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and 
      Normofractionated Proton Therapy for Localized Prostate Cancer.
LID - 10.3390/cancers14030517 [doi]
LID - 517
AB  - We retrospectively evaluated the three-year patient-reported quality of life 
      (QOL) after moderately hypofractionated proton therapy (MHPT) for localized 
      prostate cancer in comparison with that after normofractionated PT (NFPT) using 
      the Expanded Prostate Cancer Index Composite-50. Patients who received MHPT 
      (60-63 Gy (relative biological effectiveness equivalents; RBE)/20-21 fractions) 
      (n = 343) or NFPT (74-78 Gy (RBE)/37-39 fractions) (n = 296) between 2013 and 
      2016 were analyzed. The minimum clinically important difference (MCID) threshold 
      was defined as one-half of a standard deviation of the baseline value. The median 
      follow-up was 56 months and 83% completed questionnaires at 36 months. Clinically 
      meaningful score deterioration was observed in the urinary domain at 1 month in 
      both groups and in the sexual domain at 6-36 months in the NFPT group, but not 
      observed in the bowel domain. At 36 months, the mean score change for urinary 
      summary was -0.3 (MHPT) and -1.6 points (NFPT), and that for bowel summary was 
      +0.1 and -2.0 points; the proportion of patients with MCID was 21% and 24% for 
      urinary summary and 18% and 29% for bowel summary. Overall, MHPT had small 
      negative impacts on QOL over three years, and the QOL after MHPT and NFPT was 
      similar.
FAU - Nakajima, Koichiro
AU  - Nakajima K
AD  - Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City 
      University West Medical Center, Nagoya 462-8508, Japan.
FAU - Iwata, Hiromitsu
AU  - Iwata H
AUID- ORCID: 0000-0001-9809-9800
AD  - Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City 
      University West Medical Center, Nagoya 462-8508, Japan.
FAU - Hattori, Yukiko
AU  - Hattori Y
AUID- ORCID: 0000-0003-1307-7608
AD  - Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City 
      University West Medical Center, Nagoya 462-8508, Japan.
FAU - Nomura, Kento
AU  - Nomura K
AD  - Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City 
      University West Medical Center, Nagoya 462-8508, Japan.
FAU - Hayashi, Kensuke
AU  - Hayashi K
AD  - Department of Proton Therapy Technology, Nagoya Proton Therapy Center, Nagoya 
      462-8508, Japan.
FAU - Toshito, Toshiyuki
AU  - Toshito T
AUID- ORCID: 0000-0002-6762-0015
AD  - Department of Proton Therapy Physics, Nagoya Proton Therapy Center, Nagoya 
      462-8508, Japan.
FAU - Umemoto, Yukihiro
AU  - Umemoto Y
AD  - Department of Urology, Nagoya City University West Medical Center, Nagoya 
      462-8508, Japan.
FAU - Hashimoto, Shingo
AU  - Hashimoto S
AUID- ORCID: 0000-0002-7525-0288
AD  - Department of Radiology, Nagoya City University Graduate School of Medical 
      Sciences, Nagoya 467-8601, Japan.
FAU - Ogino, Hiroyuki
AU  - Ogino H
AD  - Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City 
      University West Medical Center, Nagoya 462-8508, Japan.
FAU - Shibamoto, Yuta
AU  - Shibamoto Y
AD  - Department of Radiology, Nagoya City University Graduate School of Medical 
      Sciences, Nagoya 467-8601, Japan.
AD  - Department of Radiation Oncology, Narita Memorial Proton Center, Toyohashi 
      441-8021, Japan.
LA  - eng
GR  - 20K16830/Japan Society for the Promotion of Science/
PT  - Journal Article
DEP - 20220120
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC8833499
OTO - NOTNLM
OT  - EPIC-50
OT  - moderately hypofractionation
OT  - prostate cancer
OT  - proton therapy
OT  - quality of life
COIS- The authors declare no conflict of interest.
EDAT- 2022/02/16 06:00
MHDA- 2022/02/16 06:01
PMCR- 2022/01/20
CRDT- 2022/02/15 01:03
PHST- 2021/12/15 00:00 [received]
PHST- 2022/01/12 00:00 [revised]
PHST- 2022/01/18 00:00 [accepted]
PHST- 2022/02/15 01:03 [entrez]
PHST- 2022/02/16 06:00 [pubmed]
PHST- 2022/02/16 06:01 [medline]
PHST- 2022/01/20 00:00 [pmc-release]
AID - cancers14030517 [pii]
AID - cancers-14-00517 [pii]
AID - 10.3390/cancers14030517 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Jan 20;14(3):517. doi: 10.3390/cancers14030517.